CICIC DRAGAN
Known title: SVP, Chief Development OfficerCIK: 0001565795
Associated companies
Transaction History
| SLS | ▲ Buy | Grant | 300,000 | $0 | 1/7/2026 | View on chart |
| SLS | ▼ Sell | Other | 63,800 | $96K | 12/3/2025 | View on chart |
| SLS | ▲ Buy | Grant | 113,000 | $0 | 1/10/2025 | View on chart |
| SLS | ▲ Buy | Grant | 81,300 | $0 | 1/10/2025 | View on chart |
| SLS | ▼ Sell | Other | 8,256 | $9K | 12/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study
SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.